138 related articles for article (PubMed ID: 2671289)
1. A comparison of carboplatin plus methotrexate versus methotrexate alone in patients with recurrent and metastatic head and neck cancer.
Eisenberger M; Krasnow S; Ellenberg S; Silva H; Abrams J; Sinibaldi V; Van Echo D; Aisner J
J Clin Oncol; 1989 Sep; 7(9):1341-5. PubMed ID: 2671289
[TBL] [Abstract][Full Text] [Related]
2. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study.
Forastiere AA; Metch B; Schuller DE; Ensley JF; Hutchins LF; Triozzi P; Kish JA; McClure S; VonFeldt E; Williamson SK
J Clin Oncol; 1992 Aug; 10(8):1245-51. PubMed ID: 1634913
[TBL] [Abstract][Full Text] [Related]
3. Prospective randomized trial of one-hour sequential versus simultaneous methotrexate plus 5-fluorouracil in advanced and recurrent squamous cell head and neck cancer.
Browman GP; Archibald SD; Young JE; Hryniuk WM; Russell R; Kiehl K; Levine MN
J Clin Oncol; 1983 Dec; 1(12):787-92. PubMed ID: 6366132
[TBL] [Abstract][Full Text] [Related]
4. Randomised phase II study of methotrexate (MTX) versus methotrexate plus lonidamine (MTX + LND) in recurrent and/or metastatic carcinoma of the head and neck.
Colella E; Merlano M; Blengio F; Angelini F; Ausili Cefaro GP; Scasso F; Lo Russo V; Cirulli S; Giannarelli D; Cognetti F
Eur J Cancer; 1994; 30A(7):928-30. PubMed ID: 7946585
[TBL] [Abstract][Full Text] [Related]
5. A phase I-II trial of carboplatin and 5-fluorouracil combination chemotherapy in advanced carcinoma of the head and neck.
Forastiere AA; Natale RB; Takasugi BJ; Goren MP; Vogel WC; Kudla-Hatch V
J Clin Oncol; 1987 Feb; 5(2):190-6. PubMed ID: 3543242
[TBL] [Abstract][Full Text] [Related]
6. Modulation of the antitumor effect of methotrexate by low-dose leucovorin in squamous cell head and neck cancer: a randomized placebo-controlled clinical trial.
Browman GP; Goodyear MD; Levine MN; Russell R; Archibald SD; Young JE
J Clin Oncol; 1990 Feb; 8(2):203-8. PubMed ID: 2405105
[TBL] [Abstract][Full Text] [Related]
7. Randomized phase III trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck: a European Organization for Research and Treatment of Cancer Head and Neck Cancer Cooperative Group study.
Schornagel JH; Verweij J; de Mulder PH; Cognetti F; Vermorken JB; Cappelaere P; Armand JP; Wildiers J; de Graeff A; Clavel M
J Clin Oncol; 1995 Jul; 13(7):1649-55. PubMed ID: 7602354
[TBL] [Abstract][Full Text] [Related]
8. Randomized trial of neoadjuvant cisplatin and fluorouracil versus carboplatin and fluorouracil in patients with stage IV-M0 head and neck cancer.
De Andrés L; Brunet J; López-Pousa A; Burgués J; Vega M; Tabernero JM; Mesía R; López JJ
J Clin Oncol; 1995 Jun; 13(6):1493-500. PubMed ID: 7751897
[TBL] [Abstract][Full Text] [Related]
9. The application of a two-stage design for clinical trials in patients with recurrent head and neck cancer.
Eisenberger MA; Ellenberg S; Leyland-Jones B; Friedman M
Med Pediatr Oncol; 1988; 16(3):162-8. PubMed ID: 3288853
[TBL] [Abstract][Full Text] [Related]
10. A randomized comparison of high-dose infusion methotrexate versus standard-dose weekly therapy in head and neck squamous cancer.
Taylor SG; McGuire WP; Hauck WW; Showel JL; Lad TE
J Clin Oncol; 1984 Sep; 2(9):1006-11. PubMed ID: 6332178
[TBL] [Abstract][Full Text] [Related]
11. Methotrexate/fluorouracil scheduling influences normal tissue toxicity but not antitumor effects in patients with squamous cell head and neck cancer: results from a randomized trial.
Browman GP; Levine MN; Goodyear MD; Russell R; Archibald SD; Jackson BS; Young JE; Basrur V; Johanson C
J Clin Oncol; 1988 Jun; 6(6):963-8. PubMed ID: 3286831
[TBL] [Abstract][Full Text] [Related]
12. Comparison of methotrexate and sequential methotrexate-5-fluorouracil for patients with recurrent squamous cell carcinoma of the oral cavity.
Airoldi M; Pedani F; Brando V; Gabriele P; Orecchia R
Chemioterapia; 1987 Dec; 6(6):390-2. PubMed ID: 3435920
[TBL] [Abstract][Full Text] [Related]
13. [Chemotherapy with MTX, 5-FU and CDGP for treatment of newly diagnosed head and neck cancer].
Sakoda T; Morizane R; Nakahara K; Enomoto Y; Nosaka A; Enomoto T; Kitano H
Gan To Kagaku Ryoho; 2009 Sep; 36(9):1451-5. PubMed ID: 19755812
[TBL] [Abstract][Full Text] [Related]
14. A prospective randomized trial of methotrexate versus cisplatin in the treatment of recurrent squamous cell carcinoma of the head and neck.
Hong WK; Schaefer S; Issell B; Cummings C; Luedke D; Bromer R; Fofonoff S; D'Aoust J; Shapshay S; Welch J; Levin E; Vincent M; Vaughan C; Strong S
Cancer; 1983 Jul; 52(2):206-10. PubMed ID: 6190545
[TBL] [Abstract][Full Text] [Related]
15. A phase I-II trial of induction chemotherapy with carboplatin and fluorouracil in locally advanced head and neck squamous cell carcinoma: a report from the UCL-Oncology Group, Belgium.
Grégoire V; Beauduin M; Humblet Y; Hamoir M; Longueville J; Majois F; Remacle FM; Rousseau F; Salamon E; Wambersie A
J Clin Oncol; 1991 Aug; 9(8):1385-92. PubMed ID: 2072142
[TBL] [Abstract][Full Text] [Related]
16. Methotrexate treatment of advanced head and neck cancers: a dose response evaluation.
Woods RL; Fox RM; Tattersall MH
Cancer Treat Rep; 1981; 65 Suppl 1():155-9. PubMed ID: 7034929
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant methotrexate escalated to toxicity for resectable stage III and IV squamous head and neck carcinomas--a prospective, randomized study.
Rentschler RE; Wilbur DW; Petti GH; Chonkich GD; Hilliard DA; Camacho ES; Thorpe RB
J Clin Oncol; 1987 Feb; 5(2):278-85. PubMed ID: 3806169
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of methotrexate, vinblastine, doxorubicin, and cisplatin in patients with squamous cell carcinoma of the upper respiratory or alimentary passages of the head and neck.
Okuno SH; Mailliard JA; Suman VJ; Edmonson JH; Creagan ET; Nair S; Levitt R; Kugler JW
Cancer; 2002 Apr; 94(8):2224-31. PubMed ID: 12001121
[TBL] [Abstract][Full Text] [Related]
19. Carboplatin (NSC-241-240): an active platinum analog for the treatment of squamous-cell carcinoma of the head and neck.
Eisenberger M; Hornedo J; Silva H; Donehower R; Spaulding M; Van Echo D
J Clin Oncol; 1986 Oct; 4(10):1506-9. PubMed ID: 3531424
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.
Edelman MJ; Meyers FJ; Houston J; Lauder I
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-68-S15-71. PubMed ID: 9346226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
